Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio.
Semin Respir Crit Care Med. 2020 Oct;41(5):700-715. doi: 10.1055/s-0040-1709495. Epub 2020 Aug 10.
At least 5% of sarcoidosis patients die from their disease, usually from advanced pulmonary sarcoidosis. The three major problems encountered in advanced pulmonary sarcoidosis are pulmonary fibrosis, pulmonary hypertension, and respiratory infections. Pulmonary fibrosis is the result of chronic inflammation, but other factors including abnormal wound healing may be important. Sarcoidosis-associated pulmonary hypertension (SAPH) is multifactorial including parenchymal fibrosis, vascular granulomas, and hypoxia. Respiratory infections can be cause by structural changes in the lung and impaired immunity due to sarcoidosis or therapy. Anti-inflammatory therapy alone is not effective in most forms of advanced pulmonary sarcoidosis. New techniques, including high-resolution computer tomography and 18F-fluorodeoxyglucose positron emission tomography (PET) have proved helpful in identifying the cause of advanced disease and directing specific therapy.
至少有 5%的类肉瘤病患者死于该病,通常死于晚期肺类肉瘤病。晚期肺类肉瘤病中遇到的三个主要问题是肺纤维化、肺动脉高压和呼吸道感染。肺纤维化是慢性炎症的结果,但其他因素,包括异常的伤口愈合,可能也很重要。与类肉瘤病相关的肺动脉高压(SAPH)是多因素的,包括实质纤维化、血管肉芽肿和缺氧。呼吸道感染可能是由于肺的结构变化以及类肉瘤病或治疗引起的免疫功能受损引起的。单独的抗炎治疗对大多数形式的晚期肺类肉瘤病无效。新技术,包括高分辨率计算机断层扫描和 18F-氟脱氧葡萄糖正电子发射断层扫描(PET),已被证明有助于确定晚期疾病的原因,并指导特定的治疗。